Cell Therapy Strategy
Cell Therapy Partnership Strategy
How cell therapy assets are evaluated, positioned, and structured for partnership — a 10-part series for BD teams and external innovation leads.
Why cell therapy partnering is different
Cell therapy assets do not behave like small molecules or antibodies in a deal process. Manufacturing footprint, vector supply, apheresis logistics, and site readiness are not appendices to the deal — they shape valuation, deal structure, and the partner shortlist itself. Treating them as diligence items rather than strategic inputs is the most common mistake we see in first-round partner conversations.
What the series covers
The ten installments walk through asset readiness, partner archetypes (large pharma cell therapy units, platform consolidators, regional licensees), deal architectures observed in landmark transactions, and the integration questions that determine whether a partnership creates value after signing.
Who it is written for
BD and corporate development leads at biotech asset owners; external innovation, search-and-evaluation, and licensing teams at mid-cap and large pharma; and investors holding cell therapy positions where a partnering path is part of the thesis.
For biotech partnering or asset strategy discussions, contact Kerlann Advisory.